Amgen Covering Its Bases In Hospira Biosimilars Suit
This article was originally published in Scrip
Executive Summary
Seeking to obtain more clarity on the interpretation of the Biologics Price Competition and Innovation Act (BPCIA), Amgen Inc. has filed another lawsuit involving a biosimilar of one of its products – this time Epogen (epoetin alfa), the firm's first FDA-approved therapeutic, which gained the agency's blessing in 1989.